Furthermore, while international guidelines currently recommend de-escalation strategies for low-risk HER2-positive breast cancer, real-world confirmation of their long-term efficacy and safety remains an unmet clinical need [4,5,10]. The gene discussed is ERBB2; the disease is breast carcinoma.